Veteran biotechnology executive, Daniel Passeri brings more than three decades of experience in oncology and immunotherapy drug development Interim CEO Dr. Bo Rode Hansen resumes role as member of the Board of Directors of Lift Therapeutics and assumes role as President - London, September 23, 2026 – Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Daniel Passeri, MSc, JD, as Chief Executive Officer (CEO). Mr. Passeri brings over 30 years of exp

Innovate UK Knowledge Transfer Partnerships (KTPs) connect businesses with academic expertise to turn innovative ideas into real-world impact. The KTP is a collaboration between a postgraduate (Associate), a business, and a university (Knowledge Base, this involves the Principal investigators and Knowledge base office). The KTP between Queen Mary University of London (QMUL) and LIfT Biosciences has been awarded the highest possible “Outstanding” rating and a Certificate of E

- Members include Nobel laureate James P. Allison, Padmanee Sharma, Taha Merghoub, and Kingston Mills, who are all globally renowned experts in cancer immunotherapy and translational cancer immunology - LIfT BioSciences’ lead IMAN-based drug candidate is a groundbreaking next-generation immunotherapy designed to treat patients with treatment-resistant cancers London, May 07, 2026 – LIfT BioSciences (‘LIfT’ or ‘the Company’) today announced the formation of its Sci

Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease context LIfT BioSciences’ immuno-modulatory alpha neutrophils (IMANs) are designed to have the potent anti-tumour activity of naturally occurring N1 neutrophils fixed into their biology London, April 22, 2026 – LIfT BioSciences (‘LIfT’ or ‘the Company’) today announced the publication of an article in Frontier

- Dr. Bo Rode Hansen, current Board member and Corporate Development Officer named Interim CEO - Alex Blyth, Founder and CEO to step down and will continue to work with the Company at a Board level - LIfT BioSciences is currently advancing its first IMAN-based product and preparing to initiate a first-in-human Phase 1 clinical trial. This groundbreaking next-generation immunotherapy aims to target patients with treatment-resistant cancers. London, January 7, 2026 – LIfT BioS

London, 5 November 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data demonstrating the potential of its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) to restore innate immune competence and remodel the tumour microenvironment (TME) in support of anti-tumor immunity, will be presented in a poster at the 40th Society for Immunotherapy of Cancer bein